NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), th...

Full description

Saved in:
Bibliographic Details
Main Authors SHARMA, SUDHIR, KUMAR, TREHAN, SANJAY, DAS, JAGATTARAN, JAIN, RAJESH, NANDA, GURMEET, KAUR, THUNGATHURTHI, SASTRY, V., R., S, SINGH, NISHAN
Format Patent
LanguageEnglish
French
Published 28.11.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2). Cette invention concerne de nouveaux composés de Formule (I), leurs dérivés pharmaceutiquement acceptables, leurs formes tautomères, ainsi que leurs isomères, polymorphes, promédicaments, métabolites, sels ou solvates. Cette invention concerne également des procédés de synthèse desdits nouveaux composés de Formule (I), de leurs dérivés pharmaceutiquement acceptables, de leurs formes tautomères, ainsi que de leurs isomères, polymorphes, promédicaments, métabolites, sels ou solvates. Des compositions pharmaceutiques comprenant les nouveaux composés de Formule (I) et des méthodes pour traiter ou prévenir une ou plusieurs affections ou maladies qui peuvent être régulées ou normalisées par inhibition du co-transporteur 2 de sodium-glucose (SGLT-2) sont également décrites.
Bibliography:Application Number: WO2012IN00612